Hatch’s Swan Song: A Bill to Block Generic Companies’ IPR Filings image

RAPS Regulatory Focus, December 14, 2018
by Zachary Brennan, quoting Jonathan Darrow (Student Fellow Alumnus)

Links

Read the Full Article

From the article: 

Retiring Sen. Orrin Hatch (R-UT) and two Republican colleagues in the House and Senate proposed a bill earlier this week to prevent generic drug applicants from taking advantage of the inter partes review (IPR) created under the America Invents Act.

The bill, known as the Hatch-Waxman Integrity Act of 2018, would require a generic manufacturer wishing to challenge a brand-name drug patent to choose between the Hatch-Waxman legal framework and the IPR.

Generic drugmakers have embraced the IPR and successfully challenged patents about 50% of the time, according to a recent study published in Applied Health Economics and Health Policy.

Read more here!

pharmaceuticals regulation